Understanding cognitive decline and mild cognitive impairment in Alzheimer's disease
AlfaCognition: Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.
This study looks at how people with different levels of memory issues, including those with Alzheimer's, feel about their cognitive decline to better understand how it progresses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 45 Years and up |
| Sex | All |
| Sponsor | Barcelonabeta Brain Research Center, Pasqual Maragall Foundation Academic / other |
| Locations | 1 site (Barcelona, Catalonia) |
| Trial ID | NCT03851523 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the phases of subjective perception of cognitive decline and mild cognitive impairment associated with Alzheimer's disease. It involves assessing cognitively healthy individuals, those with subjective cognitive decline, mild cognitive impairment, and mild dementia. Participants will be evaluated through subjective memory complaints and clinical interviews, with the involvement of a relative to provide additional insights. The study seeks to enhance understanding of the progression of cognitive decline in Alzheimer's disease without any direct interventions.
Who should consider this trial
Good fit: Ideal candidates include men and women aged 45 to 74 with subjective cognitive decline, mild cognitive impairment, or mild dementia.
Not a fit: Patients with significant systemic illnesses or cognitive impairments unrelated to Alzheimer's disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve early detection and understanding of cognitive decline in Alzheimer's disease, leading to better patient management.
How similar studies have performed: Other studies have shown success in understanding cognitive decline in Alzheimer's disease, making this approach relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men and women between 45 and 74 years at the time of inclusion in the 45-65/FPM2012 study or older than 45 for persons who have not previously participated in 45-65/FPM2012. 2. Cognitively healthy persons with SCD, as well as people with MCI and mild dementia. 3. Participation of a relative to perform the subjective memory complaint and clinical interview. Exclusion criteria: 1. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol. 2. Any significant disorder that could course with cognitive impairment that is not related to AD. 3. Family history of monogenic AD.
Where this trial is running
Barcelona, Catalonia
- Barcelonabeta Brain Research Center — Barcelona, Catalonia, Spain (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.